Vilija Oke

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity.

Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity.

Journal: Lupus science & medicine

Published: November 13, 2025

CD72 downregulation on DN2 B cells is associated with disease activity and resistance to rituximab in systemic lupus erythematosus.

CD72 downregulation on DN2 B cells is associated with disease activity and resistance to rituximab in systemic lupus erythematosus.

Journal: Rheumatology (Oxford, England)

Published: October 28, 2025

Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study.

Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study.

Journal: Rheumatology and therapy

Published: October 08, 2025

Interleukin 16 in lupus nephritis-a role for Th1 and CD8+ T cell migration.

Interleukin 16 in lupus nephritis-a role for Th1 and CD8+ T cell migration.

Journal: Clinical and experimental immunology

Published: June 27, 2025

Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies.

Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies.

Journal: Annals of the rheumatic diseases

Published: November 28, 2024

Role of interleukin-16 in human diseases: a novel potential therapeutic target.

Role of interleukin-16 in human diseases: a novel potential therapeutic target.

Journal: Frontiers in immunology

Published: November 06, 2024

Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection.

Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection.

Journal: QJM : monthly journal of the Association of Physicians

Published: January 04, 2024

Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patients.

Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patients.

Journal: Rheumatology (Oxford, England)

Published: October 30, 2023

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis.

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis.

Journal: Lupus science & medicine

Published: June 04, 2022

Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy.

Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy.

Journal: International journal of molecular sciences

Published: September 07, 2021

Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations.

Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations.

Journal: ACR open rheumatology

Published: July 10, 2021

Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE.

Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE.

Journal: Arthritis research & therapy

Published: January 10, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026